Reviewed by: Jose Baldazo - RN, BSN
If you've spent any time in the longevity world — reading about NAD+, VO2 max protocols, or the latest biomarker panel some biohacker swears by — you may have noticed something: almost none of it was built with women in mind.
That's not an accident, and it's not paranoia. It's the direct result of decades of research design that treated the male body as the default and extrapolated everything else from there. For women managing hormone shifts after 35, that gap isn't academic — it shows up as confusing labs, dismissed symptoms, and treatment plans that quietly assume a physiology you don't have.
Here's what actually happened, what it means for your biomarkers today, and what's finally starting to change.
The data gap nobody talks about
In 1977, the FDA issued guidance that effectively excluded women of childbearing age from early-phase drug trials — a reaction to the thalidomide crisis, but one with a long tail. That exclusion held for over a decade, and it wasn't until the NIH Revitalization Act of 1993 that including women in federally funded research became law rather than a suggestion.
Progress since then has been real but incomplete. A cross-sectional study of more than 20,000 clinical trials run between 2000 and 2020 found that female participants remained underrepresented relative to disease burden in oncology, neurology, immunology, and nephrology — and that cardiology trials showed some of the steepest gaps. Even now, women make up less than 40% of participants in heart disease and stroke research, despite cardiovascular disease being a leading cause of death in women.
Longevity medicine inherited all of this. Fasting protocols, resistance-training guidelines, supplement dosing, and "optimal" biomarker ranges were mostly established in male-dominated studies, then applied to women with a mental asterisk that nobody ever resolved.
What "male-default" medicine misses
This isn't just a research footnote — it changes what happens in the exam room.
Symptoms get misread. Fatigue, brain fog, and mood changes in a 40-year-old woman are routinely chalked up to stress or "just getting older" instead of being investigated as hormonal.
Reference ranges don't flex with your cycle or your decade. Many standard lab ranges weren't built to account for the hormonal shifts of perimenopause, let alone the difference between a 28-year-old's baseline and a 48-year-old's.
Drug dosing assumes a male metabolism. Everything from sleep medications to statins has, historically, been dosed based on trials skewed toward male participants — which matters, because women metabolize many drugs differently.
"Longevity" gets defined by male aging patterns. Cardiovascular risk, bone density loss, and metabolic changes accelerate differently — and often faster — around perimenopause and menopause, but most longevity protocols don't adjust for that inflection point at all.
The result: women get told their labs are "normal" while feeling anything but.
Female biomarkers that deserve more attention
If you're 35 or older and only getting a basic metabolic panel and a cholesterol check once a year, you're missing most of the picture. A few biomarkers worth pushing your provider to test — and worth asking about at your next visit here:
A full hormone panel — estradiol, progesterone, FSH, and testosterone (yes, women need testosterone tracked too) — rather than a single estrogen number in isolation.
Thyroid panel beyond TSH — including free T3, free T4, and thyroid antibodies, since subclinical thyroid issues disproportionately affect women and are frequently missed on TSH alone.
Ferritin and iron studies — iron deficiency is common in women and mimics fatigue-related hormonal symptoms closely enough to be misdiagnosed.
Fasting insulin and HbA1c, not just fasting glucose — insulin resistance often shows up years before glucose does, and this shift accelerates around perimenopause.
Bone density markers — bone loss can begin accelerating in the perimenopausal window, well before a standard DEXA scan is typically ordered.
hs-CRP (inflammation) — useful context for cardiovascular risk, which climbs faster in women after menopause than most patients realize.
Hormone health after 35: what's actually changing in your body
Perimenopause doesn't start at menopause — for many women it begins in their late 30s to mid-40s, often years before periods become irregular. During this window:
Progesterone typically declines first and fastest, which can show up as sleep disruption and anxiety long before any "hot flash" symptoms appear.
Estrogen fluctuates unpredictably rather than dropping in a straight line, which is part of why symptoms can feel inconsistent month to month.
Testosterone — often ignored entirely in women's labs — also declines gradually, contributing to changes in energy, libido, and muscle maintenance.
Metabolic changes (insulin sensitivity, fat distribution, muscle mass) tend to shift meaningfully during this window, independent of diet or exercise habits staying the same.
None of this is discussed at a standard annual physical. It's discussed in a longevity-informed, hormone-aware visit — which is exactly the gap this piece is about.
What's changing now
The good news: the industry is starting to correct course, even if slowly. The Global Wellness Summit's 2026 trend report named women's longevity as one of its defining trends for the year, predicting that clinics, wearables, diagnostics, and telehealth platforms will increasingly reorient around female biology rather than treating it as a variant of male biology. The NIH's Office of Research on Women's Health continues to push for closing enrollment and funding gaps, and awareness of the historical exclusion is finally reaching mainstream health journalism rather than staying in research circles.
Practically, that shift shows up as: more clinics offering female-specific hormone panels as standard rather than optional, more providers trained to treat perimenopause as a distinct clinical phase rather than "not menopause yet," and more longevity protocols built with sex-specific baselines instead of one-size-fits-all ranges.
What we're seeing in our own patients
This gap isn't abstract to us — we see it in our own patient data. The majority of our patients are women. Yet the majority of our longevity patients — people actively enrolled in a structured longevity plan — are men.
That split doesn't mean our female patients are less interested in aging well. It means most of them are already doing real work in this direction without anyone framing it as longevity care. Women coming through our practice are, on average, halfway there already: they're focused on hormone optimization and weight loss, which are two of the foundational pillars any longevity plan needs. What's missing for most of them is the next layer — a customized peptide and supplement regimen built on top of that foundation — the piece that would take a hormone-and-weight-focused plan and turn it into a complete longevity plan.
In other words: the gap for our female patients isn't motivation or effort. It's that longevity medicine hasn't historically packaged itself in a way that met them where they already were.
Where this leaves you
If you're over 35 and your care so far has consisted of a basic panel and a "you're fine" — that's not a personal failure, and it's not in your head. It's the predictable result of a system that took 16 years just to require women's inclusion in trials, and decades more to start correcting for it in practice.
The fix isn't complicated: work with a provider who tests the full hormonal picture, tracks how your biomarkers shift across the decade rather than against a generic reference range, and treats perimenopause as a phase worth planning for — not a diagnosis you wait to receive.
If you're already working on hormone optimization or weight loss, you're closer to a full longevity plan than you might think. The next step is usually a customized peptide and supplement regimen built around your existing labs and goals — the piece that turns two good habits into a complete, personalized plan.
Frequently Asked Questions
Why weren't women included in early clinical research? The FDA excluded women of childbearing age from early-phase drug trials starting in 1977, largely in response to the thalidomide crisis. That policy wasn't reversed in federal law until the NIH Revitalization Act of 1993.
What biomarkers should women test after 35? A full hormone panel (estradiol, progesterone, FSH, testosterone), complete thyroid panel, ferritin/iron studies, fasting insulin, hs-CRP, and bone density markers give a far more complete picture than a standard annual panel.
When does perimenopause actually start? For many women, hormonal shifts begin in the late 30s to mid-40s — often years before periods become irregular or classic symptoms like hot flashes appear.
Is testosterone relevant for women's health? Yes. Testosterone naturally declines with age in women and affects energy, libido, and muscle maintenance, but it's rarely included in standard hormone testing.
Sources & Further Reading
National Institutes of Health, Office of Research on Women's Health — History of Women's Participation in Clinical Research. Primary source on the 1977 FDA exclusion policy and the 1993 Revitalization Act. https://orwh.od.nih.gov/toolkit/recruitment/history
National Library of Medicine (PMC) — Twenty-year cross-sectional analysis of female participation in clinical trials, 2000–2020. Peer-reviewed data on the ongoing enrollment gap by disease area. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214160/
Mayo Clinic — Perimenopause: Symptoms & Causes. Clinical overview of perimenopause onset age, hormonal changes, and symptoms. https://www.mayoclinic.org/diseases-conditions/perimenopause/symptoms-causes/syc-20354666
Global Wellness Summit — 2026 Wellness Trends Report. Industry trend analysis naming women's longevity as a defining category shift. https://www.globalwellnesssummit.com/2026trends/
NIH National Academies Press — Women's Health Research: Progress, Pitfalls, and Promise. Background on NIH Revitalization Act implementation and compliance tracking. https://www.nap.edu/read/12908/chapter/3